Fiduciary Trust Co Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Fiduciary Trust Co lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,146 shares of the medical research company’s stock after selling 51 shares during the period. Fiduciary Trust Co’s holdings in IQVIA were worth $1,456,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. PGGM Investments raised its position in IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. increased its holdings in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Raymond James & Associates lifted its stake in shares of IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares during the period. Versor Investments LP purchased a new stake in IQVIA during the third quarter worth $1,328,000. Finally, Gradient Investments LLC grew its position in IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock valued at $9,600,000 after buying an additional 6,134 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.2 %

Shares of IQVIA stock opened at $200.96 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock’s 50 day simple moving average is $218.67 and its 200-day simple moving average is $226.20. The stock has a market cap of $36.47 billion, a P/E ratio of 26.37, a P/E/G ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Evercore ISI lowered their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. TD Cowen lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Finally, Morgan Stanley dropped their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.